floxuridine has been researched along with Dihydropyrimidine Dehydrogenase Deficiency in 3 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Dihydropyrimidine Dehydrogenase Deficiency: An autosomal recessive disorder affecting DIHYDROPYRIMIDINE DEHYDROGENASE and causing familial pyrimidinemia. It is characterized by thymine-uraciluria in homozygous deficient patients. Even a partial deficiency in the enzyme leaves individuals at risk for developing severe 5-FLUOROURACIL-associated toxicity.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| De Luca, O | 3 |
| Salerno, G | 3 |
| De Bernardini, D | 3 |
| Torre, MS | 3 |
| Simmaco, M | 3 |
| Lionetto, L | 3 |
| Gentile, G | 3 |
| Borro, M | 3 |
| Lumish, M | 1 |
| Thackray, J | 1 |
| Do, RKG | 1 |
| Caudle, KE | 1 |
| Amstutz, U | 1 |
| Schwab, M | 1 |
| Diasio, RB | 1 |
| Jarnagin, WR | 1 |
| Cercek, A | 1 |
| Lee, A | 1 |
| Ezzeldin, H | 1 |
| Fourie, J | 1 |
| Diasio, R | 1 |
1 review available for floxuridine and Dihydropyrimidine Dehydrogenase Deficiency
| Article | Year |
|---|---|
Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy.
Topics: Antidotes; Antimetabolites, Antineoplastic; Biotransformation; Deoxyuracil Nucleotides; Diarrhea; Di | 2004 |
2 other studies available for floxuridine and Dihydropyrimidine Dehydrogenase Deficiency
| Article | Year |
|---|---|
Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2022 |
Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2022 |
Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2022 |
Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2022 |
Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2022 |
Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2022 |
Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2022 |
Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2022 |
Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of
Topics: Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydroge | 2022 |
Precision Management of a Patient With Dihydropyrimidine Dehydrogenase Deficiency and Liver-Predominant Metastatic Rectal Cancer Using Hepatic Arterial Floxuridine.
Topics: Dihydropyrimidine Dehydrogenase Deficiency; Floxuridine; Humans; Liver Neoplasms; Rectal Neoplasms | 2023 |